↓ Skip to main content

A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer

Overview of attention for article published in Breast Cancer Research and Treatment, November 2011
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
35 Dimensions

Readers on

mendeley
39 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer
Published in
Breast Cancer Research and Treatment, November 2011
DOI 10.1007/s10549-011-1858-7
Pubmed ID
Authors

Michaela J. Higgins, Tatiana M. Prowell, Amanda L. Blackford, Celia Byrne, Nagi F. Khouri, Shannon A. Slater, Stacie C. Jeter, Deborah K. Armstrong, Nancy E. Davidson, Leisha A. Emens, John H. Fetting, Pendleton P. Powers, Antonio C. Wolff, Hannah Green, Jacklyn N. Thibert, James M. Rae, Elizabeth Folkerd, Mitchell Dowsett, Roger S. Blumenthal, Judy E. Garber, Vered Stearns

Abstract

Observational studies have demonstrated a decreased incidence of cancers among users of HMG CoA reductase inhibitors (statins) and a reduced risk of recurrence among statin users diagnosed with early stage breast cancer. We initiated a prospective study to identify potential biomarkers of simvastatin chemopreventive activity that can be validated in future trials. The contralateral breast of women with a previous history of breast cancer was used as a high-risk model. Eligible women who had completed all planned treatment of a prior stage 0-III breast cancer received simvastatin 40 mg orally daily for 24-28 weeks. At baseline and end-of-study, we measured circulating concentrations of high-sensitivity C-reactive protein (hsCRP), estrogens, and fasting lipids; breast density on contralateral breast mammogram; and quality of life by Rand Short Form 36-Item health survey. Fifty women were enrolled with a median age of 53 years. Total cholesterol, LDL cholesterol, triglyceride, and hsCRP fell significantly during the study (P values < 0.001, <0.001, 0.003, and 0.05, respectively). Estrone sulfate concentrations decreased with simvastatin treatment (P = 0.01 overall), particularly among post-menopausal participants (P = 0.006). We did not observe a significant change in circulating estradiol or estrone concentrations, contralateral mammographic breast density, or reported physical functioning or pain scores. This study demonstrates the feasibility of short-term biomarker modulation studies using the contralateral breast of high-risk women. Simvastatin appears to modulate estrone sulfate concentrations and its potential chemopreventive activity in breast cancer warrants further investigation.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Denmark 1 3%
Unknown 38 97%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 7 18%
Student > Master 7 18%
Student > Ph. D. Student 4 10%
Other 3 8%
Professor 2 5%
Other 5 13%
Unknown 11 28%
Readers by discipline Count As %
Medicine and Dentistry 11 28%
Agricultural and Biological Sciences 5 13%
Biochemistry, Genetics and Molecular Biology 4 10%
Nursing and Health Professions 2 5%
Social Sciences 1 3%
Other 1 3%
Unknown 15 38%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 November 2011.
All research outputs
#3,108,076
of 4,506,407 outputs
Outputs from Breast Cancer Research and Treatment
#755
of 1,163 outputs
Outputs of similar age
#44,258
of 73,184 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#20
of 42 outputs
Altmetric has tracked 4,506,407 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,163 research outputs from this source. They receive a mean Attention Score of 3.9. This one is in the 27th percentile – i.e., 27% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 73,184 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one is in the 38th percentile – i.e., 38% of its contemporaries scored the same or lower than it.